Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

silver sulfadiazine

&times

Overview

What is SSD?

SSD (1% Silver Sulfadiazine) Cream and SSD AF (1% Silver Sulfadiazine) Cream are topical antibacterial preparations which have as their active antimicrobial ingredient silver sulfadiazine. The active moiety is contained within an opaque, white, water miscible cream base.

Each 1000 grams of SSD/SSD AF Cream contains 10 grams of silver sulfadiazine

Inactive Ingredients

Silver sulfadiazine has an emprical formula of CHAgNOS, molecular weight of 357.14 and structural formula as shown:



What does SSD look like?



What are the available doses of SSD?

Sorry No records found.

What should I talk to my health care provider before I take SSD?

Sorry No records found

How should I use SSD?

Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.


What interacts with SSD?

Silver Sulfadiazine Cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation.


Because sulfonamide therapy is known to increase the possibility of kernicterus, Silver Sulfadiazine Cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.



What are the warnings of SSD?

Salsalate contains a salicylate and therefore is not recommended for use in patients with chicken pox, influenza, or flu symptoms.

There is potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction.

Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low.

The use of Silver Sulfadiazine Cream in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.


What are the precautions of SSD?

General: If hepatic and renal functions become impaired and elimination of drug decreases, accumulation may occur and discontinuation of Silver Sulfadiazine Cream should be weighed against the therapeutic benefit being achieved.

In considering the use of topical proteolytic enzymes in conjunction with Silver Sulfadiazine Cream, the possibility should be noted that silver may inactivate such enzymes.

Laboratory Tests

Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests.

Carcinogenesis and Mutagenesis and Impairment of Fertility

Long-term dermal toxicity studies of 24 months duration in rats and 18 months in mice with concentrations of silver sulfadiazine three to ten times the concentration in Silver Sulfadiazine Cream revealed no evidence of carcinogenicity.

Pregnancy: Pregnancy Category B

See CONTRAINDICATIONS

Nursing Mothers

It is not known whether Silver Sulfadiazine Cream is excreted in human milk. However, sulfonamides are known to be excreted in human milk, and all sulfonamides derivatives are known to increase the possibility of kernicterus. Because of the possibility for serious adverse reactions in nursing infants from sulfonamides, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in children have not been established. (


What are the side effects of SSD?

Several cases of transient leukopenia have been reported in patients receiving silver sulfadiazine therapy. Leukopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within two to four days of initiation of therapy. Rebound to normal leukocyte levels follows onset within two to three days. Recovery is not influenced by continuation of silver sulfadiazine therapy. The incidence of leukopenia in various reports averages about 20%. A higher incidence has been seen in patients treated concurrently with cimetidine.

Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis.

Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial thickness burns by preventing conversion of the partial thickness to full thickness by sepsis. However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture.

Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias, including agranulocytosis, aplastic anemia, thrombocytopenia, leucopenia and hemolytic anemia, dermatologic and and allergic reactions, including Stevens-Johnson syndrome and exfoliative dermatitis, gastrointestinal reactions, hepatitis and hepatocellular necrosis, CNS reactions, and toxic nephrosis.


What should I look out for while using SSD?

Silver Sulfadiazine Cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation.

Because sulfonamide therapy is known to increase the possibility of kernicterus, Silver Sulfadiazine Cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

There is potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction.

Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low.

The use of Silver Sulfadiazine Cream in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.


What might happen if I take too much SSD?

Sorry No Records found


How should I store and handle SSD?

Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution. Each bottle is supplied in a child-resistant container. The amount of fentanyl contained in Lazanda can be fatal to a child, individual for whom it is not prescribed or non-opioid tolerant adult. Patients and their caregivers must be instructed to keep Lazanda out of the reach of children [seeand].Store at up to 25°C. Do not freeze.Return the bottle to the child-resistant container after each use. Put the bottle in its child-resistant container and the pouch in the cardboard carton and store securely out of the reach of children and protect from light.Note: Carton and bottle label colors are a secondary aid in product identification. Confirm the printed dosage before dispensingLazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution. Each bottle is supplied in a child-resistant container. The amount of fentanyl contained in Lazanda can be fatal to a child, individual for whom it is not prescribed or non-opioid tolerant adult. Patients and their caregivers must be instructed to keep Lazanda out of the reach of children [seeand].Store at up to 25°C. Do not freeze.Return the bottle to the child-resistant container after each use. Put the bottle in its child-resistant container and the pouch in the cardboard carton and store securely out of the reach of children and protect from light.Note: Carton and bottle label colors are a secondary aid in product identification. Confirm the printed dosage before dispensingLazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution. Each bottle is supplied in a child-resistant container. The amount of fentanyl contained in Lazanda can be fatal to a child, individual for whom it is not prescribed or non-opioid tolerant adult. Patients and their caregivers must be instructed to keep Lazanda out of the reach of children [seeand].Store at up to 25°C. Do not freeze.Return the bottle to the child-resistant container after each use. Put the bottle in its child-resistant container and the pouch in the cardboard carton and store securely out of the reach of children and protect from light.Note: Carton and bottle label colors are a secondary aid in product identification. Confirm the printed dosage before dispensingLazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution. Each bottle is supplied in a child-resistant container. The amount of fentanyl contained in Lazanda can be fatal to a child, individual for whom it is not prescribed or non-opioid tolerant adult. Patients and their caregivers must be instructed to keep Lazanda out of the reach of children [seeand].Store at up to 25°C. Do not freeze.Return the bottle to the child-resistant container after each use. Put the bottle in its child-resistant container and the pouch in the cardboard carton and store securely out of the reach of children and protect from light.Note: Carton and bottle label colors are a secondary aid in product identification. Confirm the printed dosage before dispensingLazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution. Each bottle is supplied in a child-resistant container. The amount of fentanyl contained in Lazanda can be fatal to a child, individual for whom it is not prescribed or non-opioid tolerant adult. Patients and their caregivers must be instructed to keep Lazanda out of the reach of children [seeand].Store at up to 25°C. Do not freeze.Return the bottle to the child-resistant container after each use. Put the bottle in its child-resistant container and the pouch in the cardboard carton and store securely out of the reach of children and protect from light.Note: Carton and bottle label colors are a secondary aid in product identification. Confirm the printed dosage before dispensingSSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10SSD™Cream25 gm Tube - NDC # 16590-206-2550 gm Jar - NDC # 16590-206-50400 gm Jar - NDC # 16590-206-44Store at controlled room temperature 15° - 30°C (59° - 86°F)SSD is a trademark of Dr. Reddy's Laboratories Louisiana, LLCManufactured forPar Pharmaceutical Companies, Inc.Spring Valley, NY 10977Manufactured byDr. Reddy's Laboratories Louisiana, LLCShreveport, LA 71106Rev. 05/10


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast.  Results from testing are listed below. Sufficient data have been obtained to demonstrate that silver sulfadiazine will inhibit bacteria that are resistant to other antimicrobial agents and that the compound is superior to sulfadiazine.

Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell wall to produce its bactericidal effect.

Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be useful in situations where such agents are contraindicated.

Non-Clinical Toxicology
Silver Sulfadiazine Cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation.

Because sulfonamide therapy is known to increase the possibility of kernicterus, Silver Sulfadiazine Cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

There is potential cross-sensitivity between silver sulfadiazine and other sulfonamides. If allergic reactions attributable to treatment with silver sulfadiazine occur, continuation of therapy must be weighed against the potential hazards of the particular allergic reaction.

Fungal proliferation in and below the eschar may occur. However, the incidence of clinically reported fungal superinfection is low.

The use of Silver Sulfadiazine Cream in some cases of glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as hemolysis may occur.

Prazosin hydrochloride has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides – digitalis and digoxin; (2) hypoglycemics – insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives – chlordiazepoxide, diazepam, and phenobarbital; (4) antigout – allopurinol, colchicine, and probenecid; (5) antiarrhythmics – procainamide, propranolol (see however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories – propoxyphene, aspirin, indomethacin, and phenylbutazone.

Addition of a diuretic or other antihypertensive agent to prazosin hydrochloride has been shown to cause an additive hypotensive effect. This effect can be minimized by reducing the prazosin hydrochloride dose to 1 to 2 mg three times a day, by introducing additional antihypertensive drugs cautiously, and then by retitrating prazosin hydrochloride based on clinical response.

Concomitant administration of prazosin hydrochloride with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension (see ).

General: If hepatic and renal functions become impaired and elimination of drug decreases, accumulation may occur and discontinuation of Silver Sulfadiazine Cream should be weighed against the therapeutic benefit being achieved.

In considering the use of topical proteolytic enzymes in conjunction with Silver Sulfadiazine Cream, the possibility should be noted that silver may inactivate such enzymes.

Laboratory Tests

Absorption of the propylene glycol vehicle has been reported to affect serum osmolality, which may affect the interpretation of laboratory tests.

Several cases of transient leukopenia have been reported in patients receiving silver sulfadiazine therapy. Leukopenia associated with silver sulfadiazine administration is primarily characterized by decreased neutrophil count. Maximal white blood cell depression occurs within two to four days of initiation of therapy. Rebound to normal leukocyte levels follows onset within two to three days. Recovery is not influenced by continuation of silver sulfadiazine therapy. The incidence of leukopenia in various reports averages about 20%. A higher incidence has been seen in patients treated concurrently with cimetidine.

Other infrequently occurring events include skin necrosis, erythema multiforme, skin discoloration, burning sensation, rashes, and interstitial nephritis.

Reduction in bacterial growth after application of topical antibacterial agents has been reported to permit spontaneous healing of deep partial thickness burns by preventing conversion of the partial thickness to full thickness by sepsis. However, reduction in bacterial colonization has caused delayed separation, in some cases necessitating escharotomy in order to prevent contracture.

Absorption of silver sulfadiazine varies depending upon the percent of body surface area and the extent of the tissue damage. Although few have been reported, it is possible that any adverse reaction associated with sulfonamides may occur. Some of the reactions which have been associated with sulfonamides are as follows: blood dyscrasias, including agranulocytosis, aplastic anemia, thrombocytopenia, leucopenia and hemolytic anemia, dermatologic and and allergic reactions, including Stevens-Johnson syndrome and exfoliative dermatitis, gastrointestinal reactions, hepatitis and hepatocellular necrosis, CNS reactions, and toxic nephrosis.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).